Publications & Posters Publications & Posters - 2022 SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response Continue Reading
Publications & Posters Publications & Posters - 2022 SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
Publications & Posters Publications & Posters - 2022 Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner. Continue Reading
Publications & Posters Publications & Posters – 2021 SITC 2021: A Phase 1 First-in-Human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies Continue Reading
Publications & Posters Publications & Posters – 2021 AACR-NCI-EORTC Virtual International Conference 2021: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1 fusion driven cancers Continue Reading
Publications & Posters Publications & Posters – 2021 American Association for Cancer Research 2021: Dual-specific antibodies that bind to BCMA and TACI (HMBD-009) enable better targeting of multiple myeloma in pre-clinical models Continue Reading
Publications & Posters Publications & Posters – 2021 AACR 2021: Dual-specific biotherapeutics targeting BCMA and TACI have the potential to overcome resistance mechanisms in multiple Myeloma Continue Reading
Publications & Posters Publications & Posters – 2020 The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody Continue Reading
Publications & Posters Publications & Posters – 2020 Molecular Cancer Therapeutics, AACR Journals: 10D1F, an anti-HER3 antibody that uniquely blocks the receptor heterodimerization interface, potently inhibits tumor growth across a broad panel of tumor models Continue Reading
Publications & Posters Publications & Posters – 2018 Journal for ImmunoTherapy of Cancer: P477 HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment Continue Reading
